What is Utak?
UTAK specializes in delivering handcrafted Quality Controls utilizing 100% real human matrices, catering to the needs of clinical and toxicology laboratories. With a legacy spanning over 50 years, the company operates as an independent QC partner, ensuring compliant and audit-ready quality without the burden of in-house manufacturing. Their comprehensive service portfolio includes custom QC formulations, rapid manufacturing processes, and detailed documentation designed to guarantee product stability and regulatory adherence. UTAK serves leading reference laboratories that seek cost certainty and dependable quality control solutions.
How much funding has Utak raised?
Utak has raised a total of $446K across 2 funding rounds:
Debt
$150K
Debt
$296K
Debt (2020): $150K with participation from PPP
Debt (2021): $296K led by PPP
What's next for Utak?
The recent large-scale late-stage funding and major strategic investment signal a period of significant growth and potential expansion for UTAK. This capital infusion is likely to bolster the company's capacity for innovation in quality control solutions and potentially broaden its market reach within the clinical and toxicology sectors. UTAK's focus on providing compliant, audit-ready quality control, coupled with its extensive experience, positions it for continued leadership and development in serving reference laboratories seeking cost-effective and reliable QC partnerships.
See full Utak company page
